Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1Phase 1 1

Status

Active not recruiting 5Recruiting 4Not yet recruiting 1Completed 1Approved for marketing 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5NET 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 4Lung Neoplasms 1Bites and Stings 1

Interventions

Carboplatin 135pembrolizumab 114Pemetrexed 95Cisplatin 89durvalumab 62Paclitaxel 60Nivolumab 55osimertinib 54Docetaxel 44atezolizumab 40Etoposide 30Radiotherapy 28Radiosurgery 26Gemcitabine 26Specimen Handling 24Ipilimumab 24Taxes 19Magnetic Resonance Spectroscopy 19amivantamab 16130-nm albumin-bound paclitaxel 16Drug Therapy 15Bevacizumab 15Radiation 14Platinum 14Immunoglobulin G 14Disulfides 14cemiplimab 13Crizotinib 13Cyclophosphamide 12Biopsy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × AMG 757 × Thoracic × Clear all
NCT06117774 2026-04-29

DeLLphi-306

Amgen

Phase 3 Active not recruiting
404 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Amgen

Phase 1 Active not recruiting
184 enrolled
Thoracic

Bites and Stings, Lung Neoplasms

NCT06745323 2026-03-03

DeLLphi-309

Amgen

Phase 2 Active not recruiting
252 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT05740566 2026-01-05

DeLLphi-304

Amgen

Phase 3 Active not recruiting
509 enrolled 11 charts 1 FDA
Thoracic

Small Cell Lung Carcinoma

NCT06211036 2025-12-17

DeLLphi-305

Amgen

Phase 3 Active not recruiting
563 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡